Motley Fool Australia

Pot stocks rocket: Here’s what you need to know

Medical Cannabis, Doctor, Marijuana

Although the market as a whole has climbed higher today, one group of shares has stood out with impressively strong gains.

These are the medicinal cannabis companies, which are better known as pot stocks.

While there doesn’t appear to have been a single catalyst for today’s gains, investor appetite for pot stocks is certainly on the rise.

Here’s the current state of play in the industry today:

The Auscann Group Holdings Ltd (ASX: AC8) share price is up 10.5% to 63.5 cents. The last bit of news out of AusCann was the receipt of a medicinal cannabis manufacture licence last week. Since then its shares have rallied as much as 37%.

The Cann Group Ltd (ASX: CAN) share price climbed as much as 22% and hit an all-time high of $1.27 today despite there being no news out of the company. Late last month Cann released its quarterly update and confirmed that this month it expects to harvest its first plant material from cultivation at its Southern facility.

The Creso Pharma Ltd (ASX: CPH) share price has climbed 5% to 53 cents. Last week Creso provided the market with an update which revealed that it is searching for a CEO of its Canadian operations following the acquisition of Mernova Medicinal. The new CEO will be responsible for pursuing commercial opportunities in the Canadian medicinal and recreational cannabis space.

The Hydroponics Company Ltd (ASX: THC) share price has rocketed 14% to 32 cents today. The last piece of news out of the diversified cannabis company was its quarterly business review at the start of the month. That update advised that following the receipt of its cannabis research licence, the company is now preparing a manufacturing licence application.

The Zelda Therapeutics Ltd (ASX: ZLD) share price is up 3.5% to 9.3 cents. At the end of last month Zelda announced that following the early success of its breast cancer research programme, the company plans to extend its research to investigate the effect of cannabinoids on cancer stem cell-like cells.

Finally, whilst I believe the industry potentially has a very bright future ahead of it, I’m holding off an investment until revenues start to be generated.

At that point I believe it will be easier to judge which of the many players in the industry will emerge as market leaders and have the greatest chance of success.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

*Returns as of 6/8/2020

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Related Articles...